Cytosorbents Corporation Company Profile (NASDAQ:CTSO)

About Cytosorbents Corporation (NASDAQ:CTSO)

Cytosorbents Corporation logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTSO
  • CUSIP: N/A
  • Web:
  • Market Cap: $151.92 million
  • Outstanding Shares: 28,133,000
Average Prices:
  • 50 Day Moving Avg: $5.14
  • 200 Day Moving Avg: $4.78
  • 52 Week Range: $3.30 - $6.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.29
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $12.18 million
  • Price / Sales: 12.47
  • Book Value: $0.28 per share
  • Price / Book: 19.29
  • EBIDTA: ($10,410,000.00)
  • Net Margins: -80.56%
  • Return on Equity: -529.95%
  • Return on Assets: -75.38%
  • Debt-to-Equity Ratio: 1.00%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.03%
  • Average Volume: 120,120 shs.
  • Beta: -0.56
  • Short Ratio: 11.86

Frequently Asked Questions for Cytosorbents Corporation (NASDAQ:CTSO)

What is Cytosorbents Corporation's stock symbol?

Cytosorbents Corporation trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents Corporation's earnings last quarter?

Cytosorbents Corporation (NASDAQ:CTSO) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.02. The company earned $3.57 million during the quarter, compared to the consensus estimate of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. View Cytosorbents Corporation's Earnings History.

When will Cytosorbents Corporation make its next earnings announcement?

Cytosorbents Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Cytosorbents Corporation.

Where is Cytosorbents Corporation's stock going? Where will Cytosorbents Corporation's stock price be in 2017?

6 brokers have issued twelve-month price targets for Cytosorbents Corporation's stock. Their predictions range from $7.00 to $24.00. On average, they anticipate Cytosorbents Corporation's stock price to reach $12.71 in the next year. View Analyst Ratings for Cytosorbents Corporation.

What are analysts saying about Cytosorbents Corporation stock?

Here are some recent quotes from research analysts about Cytosorbents Corporation stock:

  • 1. Maxim Group analysts commented, "Recall back in June of 2016 CytoSorbents entered into a Loan and Security Agreement with Western Alliance Bank, securing an initial $5 million, 4-year term loan with the option of another $5M. On June 30, 2017, the Company elected to drawdown the additional $5 million of funding available under the Loan and Security Agreement, bringing its total borrowings under the facility to $10 million." (7/5/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Who are some of Cytosorbents Corporation's key competitors?

Who are Cytosorbents Corporation's key executives?

Cytosorbents Corporation's management team includes the folowing people:

  • Al Kraus, Chairman of the Board
  • Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director
  • Kathleen P. Bloch CPA, Chief Financial Officer
  • Vincent J. Capponi, Chief Operating Officer
  • Eric G. Mortensen, Chief Medical Officer
  • Michael G. Bator, Director
  • James T. Gunton, Independent Director
  • Edward R. Jones M.D., Independent Director
  • Alan D. Sobel, Independent Director

Who owns Cytosorbents Corporation stock?

Cytosorbents Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Skylands Capital LLC (2.11%), Vanguard Group Inc. (1.61%), Advisor Group Inc. (0.19%), California Public Employees Retirement System (0.16%), PNC Financial Services Group Inc. (0.14%) and Northern Trust Corp (0.13%). Company insiders that own Cytosorbents Corporation stock include Al Kraus, Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corporation.

Who sold Cytosorbents Corporation stock? Who is selling Cytosorbents Corporation stock?

Cytosorbents Corporation's stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Inc., Vanguard Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Cytosorbents Corporation.

Who bought Cytosorbents Corporation stock? Who is buying Cytosorbents Corporation stock?

Cytosorbents Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC and PNC Financial Services Group Inc.. Company insiders that have bought Cytosorbents Corporation stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents Corporation.

How do I buy Cytosorbents Corporation stock?

Shares of Cytosorbents Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents Corporation's stock price today?

One share of Cytosorbents Corporation stock can currently be purchased for approximately $5.40.

MarketBeat Community Rating for Cytosorbents Corporation (NASDAQ CTSO)
Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytosorbents Corporation (NASDAQ:CTSO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.71 (135.34% upside)

Analysts' Ratings History for Cytosorbents Corporation (NASDAQ:CTSO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/12/2017B. RileyReiterated RatingBuy$11.25LowView Rating Details
8/8/2017HC WainwrightSet Price TargetBuy$13.00HighView Rating Details
8/8/2017Maxim GroupBoost Price TargetBuy -> Buy$10.00 -> $12.00HighView Rating Details
7/25/2017AegisReiterated RatingBuy$9.00HighView Rating Details
6/7/2017Cowen and CompanyInitiated CoverageOutperform$7.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
10/29/2015WBB SecuritiesUpgradeSpeculative Buy -> Buy$13.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Cytosorbents Corporation (NASDAQ:CTSO)
Earnings by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)
Earnings History by Quarter for Cytosorbents Corporation (NASDAQ CTSO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.07)N/AView Earnings Details
8/7/2017Q2 2017($0.06)($0.04)$3.29 million$3.57 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytosorbents Corporation (NASDAQ:CTSO)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.11)($0.11)($0.11)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.08)($0.07)($0.08)
Q4 20172($0.09)($0.08)($0.09)
(Data provided by Zacks Investment Research)


Dividend History for Cytosorbents Corporation (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytosorbents Corporation (NASDAQ:CTSO)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 6.89%
Insider Trades by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)
Insider Trades by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Eric R MortensenInsiderBuy2,500$4.04$10,100.00View SEC Filing  
6/9/2017Michael G. BatorDirectorBuy1,500$4.12$6,180.00View SEC Filing  
6/8/2017Phillip P. ChanInsiderBuy3,700$4.00$14,800.00View SEC Filing  
6/8/2017Vincent CapponiCOOBuy2,500$4.00$10,000.00View SEC Filing  
6/5/2017Phillip P. ChanInsiderBuy6,300$4.00$25,200.00View SEC Filing  
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytosorbents Corporation (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corporation (NASDAQ:CTSO)
DateHeadline logoCytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by Analysts - September 17 at 2:50 AM logoComparing Cytosorbents Corporation (CTSO) & Its Peers - September 15 at 2:14 AM logoWorld Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony - September 14 at 6:26 PM logoAferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation - September 11 at 6:17 PM logoCytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference - PR Newswire (press release) - September 6 at 5:37 PM logoCytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference - September 6 at 5:36 PM logoCytosorbents Corporation (CTSO) Expected to Announce Earnings of -$0.09 Per Share - September 6 at 4:26 AM logoCytoSorbents Highlights Important Research... - September 5 at 7:11 PM logoCytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium - September 5 at 7:11 PM logoFinancial Contrast: Koninklijke Philips NV (PHG) and Cytosorbents Corporation (CTSO) - August 30 at 6:18 PM logoCytosorbents Corporation (CTSO) Given Consensus Recommendation of "Buy" by Analysts - August 23 at 3:32 AM logo Analysts Expect Cytosorbents Corporation (CTSO) Will Post Quarterly Sales of $3.67 Million - August 20 at 3:32 AM logoCytosorbents Corporation (CTSO) Expected to Post Earnings of -$0.09 Per Share - August 18 at 6:12 PM logoCytosorbents (CTSO) Secures $719K Grant to Acutely Stabilize Severe Burn Patients - August 16 at 6:03 PM logoCytosorbents (CTSO) Secures $719K Grant to Acutely Stabilize Severe Burn Patients - - August 14 at 5:59 PM logoCytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients - August 14 at 5:59 PM logoCTSO: Product Revenue Sets New Record, Further Growth Expected in 2H - August 14 at 5:59 PM logoB. Riley Reaffirms Buy Rating for Cytosorbents Corporation (NASDAQ:CTSO) - August 12 at 5:08 PM logoCytoSorbents' (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 8 at 5:21 PM logoCytoSorbents reports 2Q loss - August 8 at 4:05 AM logoCytosorbents Corporation (CTSO) Receives "Buy" Rating from B. Riley - August 7 at 8:38 PM logoCytosorbents Corporation (CTSO) Releases Earnings Results, Beats Estimates By $0.02 EPS - August 7 at 8:08 PM logoCytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 - PR Newswire (press release) - August 7 at 6:02 PM logoCytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 - August 7 at 6:02 PM logoCytosorbents Corporation (CTSO) Scheduled to Post Quarterly Earnings on Monday - August 3 at 10:40 AM logoFrost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® - August 2 at 6:28 PM logo Brokerages Expect Cytosorbents Corporation (NASDAQ:CTSO) Will Announce Quarterly Sales of $3.29 Million - August 2 at 8:30 AM logoCytoSorbents to Report Q2 2017 Operating and Financial Results - August 1 at 6:20 PM logoCytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by Analysts - July 29 at 7:26 AM logoCytosorbents Corporation's (CTSO) Buy Rating Reiterated at Aegis - July 25 at 2:44 PM logoCytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR - PR Newswire (press release) - July 17 at 5:56 PM logoCytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR - July 17 at 12:12 PM logoCytoSorbents Awarded $1 Million STTR Phase II Contract To ... - PR Newswire (press release) - July 14 at 4:52 AM logoCytosorbents (CTSO) Secures $1M STTR Phase II Contract To ... - - July 13 at 6:51 PM logo$3.29 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter - July 9 at 10:00 AM logoZacks: Brokerages Anticipate Cytosorbents Corporation (CTSO) Will Announce Earnings of -$0.06 Per Share - July 7 at 8:55 AM logoCytoSorbents receives additional $5M in non-dilutive debt financing from Bridge Bank - July 5 at 6:24 PM logoCytosorbents Corporation (NASDAQ:CTSO) Earns "Buy" Rating from Maxim Group - July 5 at 1:58 PM logoCytosorbents Corporation (CTSO) Receives Consensus Rating of "Buy" from Brokerages - July 4 at 12:32 AM logoCytosorbents: A Razor & Razor Blade Story - June 28 at 5:31 PM logoCytoSorbents Announces Director and Management Open Market Stock Purchases - June 15 at 6:30 PM logoCytosorbents Corporation (CTSO) Expected to Post Quarterly Sales of $3.29 Million - June 15 at 11:54 AM logoABIOMED (ABMD) and Cytosorbents Corporation (CTSO) Critical Survey - June 14 at 7:50 AM logoInsider Buying: Cytosorbents Corporation (CTSO) Insider Buys 2,500 Shares of Stock - June 13 at 9:02 PM logo-$0.06 Earnings Per Share Expected for Cytosorbents Corporation (CTSO) This Quarter - June 13 at 8:20 AM logoInsider Buying: Cytosorbents Corp (CTSO) Insider Purchases 3,700 Shares of Stock - June 8 at 8:20 PM logoCytosorbents Corp (CTSO) Now Covered by Analysts at Cowen and Company - June 7 at 8:32 PM logoCytosorbents Corp (CTSO) Given Consensus Recommendation of "Buy" by Brokerages - June 7 at 8:34 AM logoCytosorbents Corp (CTSO) Insider Phillip P. Chan Buys 6,300 Shares - June 6 at 8:41 PM logoCytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors - June 6 at 4:48 PM



Cytosorbents Corporation (CTSO) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff